Evidence map›Paper›PMID 33177154›Full record

ArticleMolecular cancer therapeutics2021

Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer.

Balkees Abderrahman, Philipp Y Maximov, Ramona F Curpan, Sean W Fanning, Jay S Hanspal, Ping Fan, Charles E Foulds, Yue Chen, Anna Malovannaya, Antrix Jain and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Balkees AbderrahmanDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Philipp Y MaximovDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Ramona F CurpanCoriolan Dragulescu Institute of Chemistry, Romanian Academy, Timisoara, Romania.
Sean W FanningBen May Department for Cancer Research, University of Chicago, Chicago, Illinois.
Jay S HanspalDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Ping FanDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Charles E FouldsCenter for Precision Environmental Health and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.ORCID https://orcid.org/0000-0003-4908-1473
Yue ChenAdrienne Helis Malvin Medical Research Foundation, New Orleans, Louisiana.
Anna MalovannayaVerna and Marrs McLean Department of Biochemistry and Molecular Biology, Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, Texas.
Antrix JainMass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, Texas.ORCID https://orcid.org/0000-0002-2815-3645
Rui XiongPharmacology and Toxicology, University of Arizona, Tucson, Arizona.
Geoffrey L GreeneBen May Department for Cancer Research, University of Chicago, Chicago, Illinois.ORCID https://orcid.org/0000-0001-6894-8728
Debra A TonettiPharmacology and Toxicology, University of Arizona, Tucson, Arizona.
Gregory R J ThatcherPharmacology and Toxicology, University of Arizona, Tucson, Arizona.
V Craig JordanDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. VCJordan@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USUniversity of Arizona · USMay Institute · USHelicon Foundation · USRomanian Academy · RO

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
Strengthening Stakeholder Engagement in Human Research Protections.UL1TR002003 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KARNIK, NIRANJAN SUBHASH, MERMELSTEIN, ROBIN J. · 2016 to 2024
$33.7M
NCATS NIH HHS UL1 TR002003NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123
6 · The paper itself

Abstract

Patients with long-term estrogen-deprived breast cancer, after resistance to tamoxifen or aromatase inhibitors develops, can experience tumor regression when treated with estrogens. Estrogen's antitumor effect is attributed to apoptosis via the estrogen receptor (ER). Estrogen treatment can have unpleasant gynecologic and nongynecologic adverse events; thus, the development of safer estrogenic agents remains a clinical priority. Here, we study synthetic selective estrogen mimics (SEM) BMI-135 and TTC-352, and the naturally occurring estrogen estetrol (E

Indexed as

ApoptosisDrug Resistance, NeoplasmUnfolded Protein ResponseBenzothiazolesBiomarkers, TumorBreast NeoplasmsCell SurvivalDNA, NeoplasmEndoribonucleasesEstrogensFemaleFluorescenceGene Expression Regulation, NeoplasticHormonesHumansLigandsBenzothiazolesBiomarkers, TumorDNA, NeoplasmEndoribonucleasesERN1 protein, humanEstrogensHormonesLigandsProtein Serine-Threonine KinasesReceptors, Estrogenthioflavin TX-Box Binding Protein 1XBP1 protein, human

Identifiers

PMID33177154
PMCPMC7790886
OpenAlexW3103656585

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.